OncoMatch/Clinical Trials/NCT07038343
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
Is NCT07038343 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including AVZO-1418 and Combination Agent 1 for solid tumor cancer.
Treatment: AVZO-1418 · Combination Agent 1 · Combination Agent 2 — This study, the first clinical trial of AVZO-1418, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-1418 when administered intravenously as a monotherapy and potentially in combination therapy to patients with locally advanced or metastatic epithelial solid tumors.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Avenzo Therapeutics Recruiting Site · Gilbert, Arizona
- Avenzo Therapeutics Recruiting Site · Los Angeles, California
- Avenzo Therapeutics Recruiting Site · Denver, Colorado
- Avenzo Therapeutics Recruiting Site · New Haven, Connecticut
- Avenzo Therapeutics Recruiting Site · Washington D.C., District of Columbia
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07038343 currently recruiting?
Yes, this trial is currently recruiting patients.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify